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ABSTRACT 
HIV-1 is characterized by a high genetic diversity which poses several challenges and 
implications with regard to disease progression, drug resistance and outcome of antiretroviral 
therapy (ART). HIV-1 subtype C (HIV-1C) is the most rapidly expanding subtype accounting 
for half of the global disease and nearly all infections in Ethiopia, Southern Africa and India 
which are the regions with the highest burden of HIV-1 infection. Molecular characteristics 
of the virus in such epidemic success need to be explored to better understand this subtype. 
In the thesis, we analysed plasma samples and patient data collected during 2009-2011 in a 
large country-wide cohort, Advanced Clinical Monitoring of ART (ACM) which was 
established to evaluate the longitudinal effectiveness of ART as practiced in real life in 
Ethiopia. The overall aim was to investigate the molecular characteristics of HIV-1C and its 
impact on first line ART outcome in Ethiopia. Both genotypic and phenotypic molecular 
techniques were employed to characterize different regions of the viral genome. In papers I 
and II, population sequencing (PBSS) of the V3 loop of the HIV-1 envelope from therapy 
naïve, patients failing therapy, as well as HIV-1C sequences from Ethiopia dated 1984-2003 
was used to assess the molecular epidemiology of HIV-1C in different geographic regions 
and the trend of viral tropism over the last decades. We also investigated the utility of 
different genotypic tropism prediction tools and the impact of the predicted viral co-receptor 
tropism on the outcome of standard first line ART. Our results showed that the Ethiopian 
epidemic is still monophylogenetic, exclusively dominated by HIV-1C, CCR5 tropic viruses. 
Furthermore, baseline tropism had an impact on outcome of standard first line ART. While 
each tool predicted tropism with comparable frequency, there was yet a large discordance 
between the tools. We elucidated this discordance further in paper III by employing an in-
house phenotypic tropism method compared with the prediction by bioinformatics tools used 
in paper II as well as in vitro sensitivity of HIV-1CEth strains for the co-receptor antagonist 
maraviroc. The results showed underestimation of R5 co-receptor usage by bioinformatics 
tools and effectiveness of maraviroc in HIV-1C. Expanding the exploration further to pol 
gene, we employed PBSS and next generation sequencing (NGS) to assess the prevalence of 
surveillance drug resistance mutations (sDRM) to reverse transcriptase- and protease-
inhibitors as well as occurrence of DRM by NGS to the novel category of integrase strand 
inhibitors.  The results in paper IV showed that NGS detected sDRM associated with RT- 
and PI- inhibitors more often than PBSS and major INSTI DRMs were found in minor viral 
variants. Furthermore, DRM identified before treatment was associated with a poorer 
treatment outcome.  
In conclusion, viral tropism and drug resistance mutations at baseline have an impact on 
subsequent treatment outcome. Currently available genotypic tropism prediction tools need 
further improvement for use in HIV-1C. The Ethiopian epidemic remains uniquely 
dominated by R5 tropic HIV-1C since its introduction. Further investigations should be done 
to delineate associated molecular and epidemiological factors contributing to its uniqueness.  
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1 INTRODUCTION 
1.1 THE HIV/AIDS PANDEMIC 
Human immunodeficiency virus (HIV) was identified as the causative agent of the acquired 
immunodeficiency syndrome (AIDS) in 1983 [1] and so far more than 70 million people have 
been infected globally among whom nearly half have died. At the end of 2016, about 36.7 
million were estimated to live with HIV. In the same year, the number of the global annual 
new HIV infections was estimated to be 1.8 million while one million  people died from 
AIDS-related illnesses [2]. Globally, 53% of all people living with HIV were reported to have 
access to antiretroviral therapy (ART).     
According to recent regional HIV statistics by UNAIDS,  the Eastern and Southern Africa 
region, which includes 21 African countries, was the most heavily affected by HIV, where 
19.8 million people were living with the virus in 2016 and thus accounting for 53.9% of the 
global HIV burden. Although the estimated proportion of new infections showed a 29% 
decline between 2010 and 2016 in the region, 790,000 new infections were estimated in 
2016, accounting for 43% of global annual new HIV infections. Similarly, despite a 42% 
decline in HIV related deaths between 2010 and 2016, yet this region accounted for 42% of 
the global AIDS related deaths (with 420,000 cases) [2]. Such decline in new infections as 
well as AIDS related deaths is attributed largely to the expanded access to ART in recent 
years: 11.7 million people (60% of those living with HIV in this region) were accessing ART, 
accounting for 60% of the global ART access in 2016. 
1.2 THE HIV EPIDEMIC IN ETHIOPIA 
Ethiopia, being one of the eastern African countries, is among the most seriously affected by 
HIV. The first HIV case was reported in 1986 and in a recent report, it is estimated that 
710,000 people are living with HIV/AIDS [3]. 
Recent estimates show that the Ethiopian HIV epidemic is generalized and heterogenic with a 
high variation of prevalence between different regions, the highest being 5.2% (Gambella, 
western) and the lowest 0.7% (SNNP, Southern) [4]. According to recent Ethiopian 
Demographic and Health Survey (DHS) report, the national HIV prevalence is declining – in 
2011 it was estimated to be 1.5% which dropped down to  0.9% in 2016 where females were 
twice affected by HIV compared to males (1.2% versus 0.6%) [5]. 
ART started in 2003 in very few facilities on out of pocket basis followed by the scale up of 
free ART services in 2005 and subsequent rapid expansion which resulted in the decline of 
AIDS related deaths and HIV incidence since 2005 [6]. Annual AIDS related deaths declined 
from 44,000 to 20,000 and new infections from 131,000 to 30,000 between 2007 and 2016 
[3, 7]. By the end of 2016, about 420,000 (59% of those living with HIV) had access to ART. 
However, a national report from 2014 indicated that only 70.3% of those who ever started 
ART were on treatment at that time showing a significant number of patients lost to follow up 
(LTFU) , suggesting challenges in retention of patients in ART care [6]. Thus, while rapid 
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expansion of ART access contributed much for both the decline in new HIV infections and 
HIV related deaths, sub-optimal retention in care of ART exposed patients could serve as a 
source of transmission of drug resistant virus in the community. 
1.3 HIV-1 BIOLOGY 
1.3.1 HIV genetic diversity and phylogeny 
The term “HIV” refers to a genetically diverse group of viral variants and consists of two 
phylogenetically distinct types, namely HIV-1 and HIV-2, each resulting from cross-species 
transmissions of the simian immunodeficiency viruses (SIV) [8]. While HIV-2 consists of 
nine groups, A-I, only group A and B are represented in the epidemic [8, 9]. HIV-1 comprises 
four distinct lineages, termed groups M, N, O, and P. Being discovered first among other 
groups, Group M (major) represents the pandemic form and  is responsible for 95% of all 
HIV infections in virtually all countries of the globe [1, 10]. Group O is responsible for more 
than 100,000 cases in West-Central  Africa, Cameroon [11, 12], and in some European 
countries with colonial ties to Cameroon; Group N is responsible for handful known cases 
mainly in Cameroon, France and possibly Togo [11, 13-15], and Group P was identified in 
2009 with only two known cases in Cameroon [16].   
The major HIV-1 Group M is the most diversified genetically and further classified into nine 
subtypes (or clades) A-D, F-H, J, and K. Subtypes A and F are again subdivided into sub-
subtypes, A1-A4, and F1 and F2 [8] based on phylogenetic analysis. Furthermore, inter-
subtype recombinant viruses are observed which, if documented in at least three individuals 
without any evident epidemiologic link, will be classified as a circulating recombinant form 
(CRF) or called unique (URF), if restricted in limited number of individuals without any 
further spread [17]. Currently, there are about 90 CRFs such as AB, AC, AE, and AG etc.  
and a steadily increasing proportion, accounting for nearly 20% of HIV-1 infections [13, 18], 
showing intersubtype recombination as a substantial force in generating further diversity in 
group M [18, 19]. 
Among the nine subtypes in Group M, subtype B predominates in North America and 
Australia. Initially subtype B also dominated in Western Europe but with time the diagnosis 
of non-B subtypes has increased substantially. However, it is in sub-Saharan Africa where 
most of the viral diversity is observed accounting for 70% of the global disease burden. The 
global HIV-1 Group M burden by subtype is: C (50%) followed by A (12%), B (10%), G 
(6%), AE (5%) and D (3%) [20]. Genetic variation at the amino acid level has been estimated 
at 8-17% within subtype and 17-35% between subtypes, dependent on the subtypes compared 
and the location of the HIV-1 genome examined [13]. Such extensive genetic diversity of 
HIV-1 poses several challenges and potential implications for viral diagnosis [21], 
monitoring of the infection [22], development of drug resistance, disease progression [23], 
viral transmission, response to ART, and effective vaccine development [22, 24, 25].  
HIV-1C is the most prevalent variant among all other subtypes in group M due to its 
predominance in highly affected regions mainly southern Africa, east Africa and India, and 
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also to some extent Central Africa and Brazil [20]. It has also become the secondly most 
common subtype in e.g. Sweden and some other European countries. The first report of 
isolation of this subtype was in 1986 from an Ethiopian patient (HIV-1CEth) by Prof Anders 
Sönnerborg and colleagues [26], with two genetically distinct strains designated C and C′ 
reported to co-circulate in nearly similar prevalence in later studies [27-29]. It has been 
shown that one of the HIV-CEth-cluster is also found in other east African countries while C′ 
clade stands as an independent cluster associated to southern African strains [30]. Some 
unique features of HIV-1C which might explain its predominance in the global epidemic will 
be discussed later in this thesis.  
While published studies (small studies, mainly from central and northern part of the country) 
unanimously have shown that the Ethiopian epidemic is overwhelmingly dominated by HIV-
1C, a mix of different subtypes (A, C, D) as well as their recombinant forms with varying 
proportion has been reported to co circulate in other Eastern African countries including those 
neighbouring Ethiopia, namely  Djibouti (subtype C (66%), CRF02_AG (20%), B (8.5%), 
CRF02_AG/C (2.9% ) and K/C (2.9%) , Sudan (subtype A (46%), C (33%) and D (21%), 
and northern Kenya (subtype A (50%), C (39%), and D (11%) [31]. Thus, as increased 
human migration and mobility result in introduction of new subtypes and variants as well as 
intermixing with existing subtypes, one could hypothesize that HIV-1C dominated 
distribution in Ethiopia might have changed currently, at least in the border regions. 
1.3.2 HIV-1 Genomic Organization and replication cycle 
HIV-1 belongs to genus Lentivirus and family Retroviridae which are mainly distinguished 
by the presence of a reverse transcriptase enzyme. Its genetic material consists of two diploid 
strands of positive sense single-stranded RNAs, each approximately 10,000 nucleotides in 
length. Fifteen viral proteins are encoded in nine overlapping open reading frames as shown 
in figure 1 below.  
 
Figure 1. The HIV-1 genome. 
While gag, pol and env encode structural proteins as well as essential enzymes which are 
common to all retroviruses, vif, vpr, tat, rev, vpu, and nef encode regulatory or accessory 
proteins with the same names which are essential at various stages of the viral replication 
cycle which starts with binding to the target cell  through CD4 receptor and co-receptors [32] 
(co-receptor usage is described in upcoming section).  
 4 
The viral replication cycle consists of several steps as reviewed [33] and systematically 
depicted in figure 2 below. Different viral proteins interact with host immune mechanisms 
and play a decisive role at different steps for the successful completion of the replication 
cycle and survival.  
 
Figure 2. Main steps in HIV-1 replication cycle including key host HIV restriction factors and viral antagonists 
involved, and major class of antiretroviral drugs targeting various steps of replication cycle.  Figure adapted from 
[33] with permission (License number 4343840892840). Details of antiretroviral drugs targeting various steps of 
replication cycle will be presented in a separate section below. 
The host restriction APOBEC3G is a powerful inhibitor of reverse transcription but its 
inhibitory effect is antagonized by viral protein Vif [34] and Vpr [35], both mediating its 
proteasomal degradation and thus maintaining productive reverse transcription. Integration 
strongly favours transcriptionally active sections of the host genome [36] and once integrated, 
the provirus may remain transcriptionally inactive for years in a fraction of infected cells, a 
stage known as “latency” [37, 38]. Translated Nef and Vpr extensively modify the cellular 
environment to ensure efficient viral replication and persistence which includes the down-
regulation of host cell-surface CD4 and HLA molecules by Nef [39, 40], and cell-cycle arrest 
and induction of apoptosis by Vpr [41-43], while the reverse transcription process by itself 
have been shown to induce apoptosis [43]. Budding is antagonized by host protein 
tetherin/BST-2 which prevent the release of virions by tethering onto cell surface [44] and 
shown to provide intrinsic herd immunity to group M HIV-1 epidemic [45], but it is 
counteracted by viral Vpu [46, 47]. Thus, the virus antagonizes the host cell’s defence 
strategies using an array of proteins and establishes lifelong infection. 
1.3.3 Co-receptor tropism and switch  
In addition to the CD4 receptor, successful entry of HIV-1 to the target cell requires 
additional chemokine co-receptors, namely CCR5 and/or CXCR4. Some strains exclusively 
use CCR5 and are hence classified as R5- tropic; others exclusively use CXCR4 and hence 
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are classified as X4-tropic [48]. Individual virus variants with ability of utilizing both co-
receptors (dual) and also a mixed viral population containing both R5- and X4-tropic strains 
are termed “dual/mixed or D/M [49]. The phenotypes are  clinically relevant mainly in terms 
of the rate of disease progression [50]. 
1.3.3.1 Tropism in untreated infection (disease progression) 
Transmission of both R5- and X4-tropic variants has been reported but the vast majority of 
primary infections are R5-tropic strains regardless of transmission route [51]. For instance, a 
French study (1996-2014) which determined co-receptor usage in primary infection showed 
that 94% of the infections were by R5-tropic strains and the prevalence of X4-tropic strains 
remained stable throughout the study period both in subtype B and non B infections [52]. A 
somewhat elevated prevalence (nearly 15%) of X4/DM-tropic virus has been reported 
recently in a large cohort of seroconverters, with the vast majority of subjects harbouring R5-
tropic virus [53]. Such R5-tropic dominance during primary infection has been shown also by 
ultra-deep pyrosequencing, a method expected to detect X4-tropic minority variants [54]. 
Whether R5 dominance is due to its preferential transmission, availability of specific target 
cells, biased immune pressures limiting X4 virus, is not established yet. Nevertheless, the fact 
that in individuals with genetic CCR5 deficiency, where homozygosity is associated with 
strong resistance to HIV infection, and heterozygosity with a slower disease progression [55, 
56], supports the predominant transmission and more efficient establishment of infection by 
R5-tropic viruses than X4-tropic ones. It should be noted that prevalence of X4-tropic virus 
during primary infection vary depending on the method used to determine the tropism 
(described separately in upcoming section below) where genotypic methods predict a higher 
prevalence in general. 
In studies that have attempted to determine the prevalence of X4-tropic viruses in chronic 
HIV-1 infection, the results remain just a bit elevated than with primary infection, ranging up 
to 25% [57-59]. Also, difference in prediction by different methods remains minimal in 
chronic infection, both genotypic and phenotypic methods yielding comparable prevalence of 
X4-tropic viruses. 
With disease progression however, nearly 50% of HIV-1B infected individuals will 
experience a tropism shift as increasing amounts of X4 virus emerge [60]. Studies have 
observed that co-receptor usage switch from R5 to X4 during late stage disease is usually 
associated with rapid CD4+ T cell depletion, rapid elevation of viral load (VL) (Figure 3) and 
occurrence of AIDS defining illness [61, 62]. Nevertheless, the proportion of X4 infected 
patients rarely exceeds 50%, even in patient cohorts of very advanced and final stage of 
disease [57]. Whether such evolution towards increased X4 usage is caused by disease 
progression or that increased usage of X4 leads to rapid disease progression, as well as the 
underlying mechanism is not established yet.  
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Figure 3. The three stages of HIV disease in relation to co-receptor usage: emergence of X4-tropic population 
associated with accelerated viral load increase and rapid CD4 decline ( right panel) (Figure adapted from [57] 
with permission (License number 4343840188812). 
Tropism data on non B subtypes are limited. In earlier studies, X4 using viruses were 
reported as rare in HIV-1C, even in late stages of disease [63, 64] including Ethiopia [65]. 
However, an increase in the incidence of X4-tropic HIV-1C has been reported recently in 
patients with advanced HIV disease from South Africa and India [66, 67] as well as from 
patients failing ART in Botswana [68] which might suggest a changing epidemiology and 
ongoing evolution of X4 tropic HIV-1C in Africa. 
1.3.3.2 Tropism under ART 
Thus, the relationship between tropism and disease progression seems established, at least in 
HIV-1B infections. Unfortunately, reports on viral tropism after initiation of standard first 
line ART are relatively scarce and effect of standard ART on co-receptor usage appears 
controversial. In some studies ART had no or a limited effect in the selection of X4 virus [69, 
70]. In other studies preferential suppression of X4 viruses after ART has been reported [71, 
72] while some other studies showed switch of tropism in both directions, R5 to X4 as well as 
X4 to R5, a switch independently associated  with disease progression [73, 74] and still other 
studies reported switch during ART as rare [75]. 
Apart from their clinical relevance in terms of the rate of disease progression, studies also 
attempted to explore possible impact of these env phenotypes on treatment outcome of first 
line ART. Some claimed X4 tropism at baseline to differentially impact treatment outcome 
including rate of viral load suppression and CD4+ T cell gain [76-79] while others show 
similar rates between R5- and X4-tropic viruses at baseline [80, 81]. Difference in methods 
used to detect tropism, study design, patient population etc. imped comparison between the 
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above mentioned studies leading to controversial findings which need to be explored further. 
Moreover, most studies are based on HIV-1B and such data on HIV-1C is scarce.  
1.3.4  HIV-1 subtype C (HIV-1C) unique features 
In contrast to other subtypes in group M, HIV-1C is rapidly expanding, accounting for half of 
global disease and nearly all infections in Ethiopia, Southern Africa and India which are 
regions with a very high burden of HIV-1 infection. Such epidemic expansion of this subtype 
suggests that there might be some factors unique to this virus affecting its replication and/or 
transmission. Several studies have attempted to elucidate possible factors related to events 
during viral entry and replication. As mentioned above, HIV-1C strains predominantly use 
the CCR5 co-receptor, even in late infection [64, 65], and as CCR5 using virus are non-
syncytium-inducing and hence display less cytopathogenicity it has been speculated that this 
might contribute to their rapid expansion and spread throughout the globe [82, 83]. Some 
studies have demonstrated a relatively high transmission fitness of this subtype compared to 
others in dendritic cells, increasing the frequencies of vaginal shedding and hence higher risks 
of heterosexual and mother-to-child transmission [84]. Other studies using PBMC models 
suggested similar transmission fitness but less fitness after transmission compared to other 
subtypes [85, 86] which might imply slow disease progression, prolonged asymptomatic 
infection and more opportunities for transmission favouring epidemic spread. This implies a 
slower rate of evolution and lower probability of accumulation of mutations that might lead 
to R5 to X4 transition. A study indeed showed that HIV-1C requires accumulation of more 
mutation in the env gene than other subtypes [87] in order to switch from R5 to X4 and a 
more recent study identified two distinct mutations in the V3 loop unique to HIV-1C [88].  
Studies have further attempted to dissect the viral genome searching for an explanation of 
HIV-1C´s unique epidemic spread and success. Analysis of LTR in earlier studies revealed 
the presence of three instead of two or less NF-κB binding sites in HIV-1C than within other 
subtypes in group M [89, 90]. The extra NF-κB binding site may enhance viral gene 
expression, conferring highest transcriptional activity in HIV-1C [91] and hence higher 
replication and transmission capability. A recent study on Ethiopian HIV-1C isolates also 
revealed presence of three NF-κB binding sites irrespective of coinfection [92] and an earlier 
Indian study even demonstrated HIV-1C strains with multiple (four) NF-κB binding sites 
associated with higher plasma viral load when compared to isolates with three or less NF-κB 
binding sites and hence presumably more infectious [93]. Other studies observed a 5-amino-
acid insertion in Vpu that could modulate its function and affect the virulence of HIV-1C 
viruses [94].  
Furthermore, Nef sequences from HIV-1C display reduced ability of down-regulating CD4 
and HLA-I compared to HIV-1B, a phenomena related to an escape mutation ‘S88G’ which 
is relatively more prevalent in HIV-1C [39]. The above mentioned molecular characteristics 
ought to result in enhanced viral replication, yet HIV-1C viruses displayed lesser replication 
fitness in vitro compared to other subtypes [85]. Such observations suggest presence of some 
other components of HIV-1C that might reduce the overall replication level without altering 
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an enhanced capacity of transmission. Analysis of pol gene products from HIV-1B and HIV-
1C on overall viral replication suggested that the reverse transcription in HIV-1C results in a 
reduced accumulation of reverse transcripts and reverse transcription complexes compared to 
HIV-1B, which may lead to reduced viral replication [95]. Thus, further studies are needed to 
elucidate molecular basis of HIV-1C difference from other predominant HIV-1 subtypes. 
1.4 SEQUENCING TECHNOLOGIES FOR CHARACTERIZATION OF HIV-1 
Currently, two major sequencing technologies are in use for characterization of HIV, mainly 
focused on clinical HIV-1 drug resistance and tropism testing. 
1.4.1 Sanger sequencing 
Population-based Sanger sequencing (PBSS) has been the most used due to its relatively low 
cost and fast turnaround time. For the purpose of sequencing plasma-derived HIV-1 RNA, it 
is generally preceded by a reverse transcription with a gene-specific primer, which may be 
followed by a second-round “nested” PCR. The resulting library of double stranded PCR 
amplicon is the template for the sequencing reaction. This library is heterogeneous and 
contains a representation of the circulating HIV-1 quasispecies within a sample, which may 
be biased as a result of primer selection [96]. It is generally agreed that PBSS lacks sensitivity 
to detect minority variants that are less than 20% prevalent [97]. Conversely, minority drug 
resistance species and non-R5 viruses may have important impact on therapy outcome. 
Studies have shown that low prevalent drug resistance variants are associated with increased 
risk of treatment failure and are rapidly selected to represent the major virus population 
within weeks after starting ART [98-100], and patients with ≥2% non-R5 tropic variants have 
been reported to be associated with poorer maraviroc response [101]. Thus, a more sensitive 
sequencing approach could be beneficial for better clinical management, calling for the 
implementation of next generation sequencing (NGS) technology in the field of HIV 
research. 
1.4.2 NGS/High throughput sequencing 
To improve the sensitivity of detection of drug resistant variants, researchers have examined 
deep sequencing technologies such as NGS as an alternative to PBSS, where usually 
thousands of templates per sample from PCR amplification are clonally sequenced to obtain 
high depth coverage with thousands of reads per sample [102]. Due to their supreme 
sensitivity, platforms such as MiSeq (Illumina) can detect HIV-1 minority variants down to 
about 1% prevalence as well as reverse transcription and PCR errors caused by enzyme 
misincorporation. Using analysis of clonal samples and standard PCR conditions, Di 
Giallonardo et al. estimated such error rates at 0.08-0.16% [103]. Comparison of this method 
with conventional PBSS showed > 99% nucleotide concordance (sensitivity, 97.4%; 
specificity, 99.3%) [102]. Oversampling or redundant sampling of sequence variants derived 
from a low input copy numbers of HIV-1 RNA/DNA templates is a potential issue in all NGS 
methods [104], and the need for multidisciplinary team (wet-lab and in silico) is another 
bottleneck for implementation of NGS [100]. Despite the shortcomings, high throughput 
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NGS have been shown to be a promising approach for widespread individual drug resistance 
testing as well as surveillance in resource limited settings (RLS), with an added advantage of 
cost-effectiveness [100, 102, 105] and its application to multiple HIV subtypes [102]. Thus, 
we chose MiSeq (Illumina) for analysis of minority drug resistance variants in this thesis. 
1.5 ANTI-HIV-1 DRUGS AND MONITORING OF ART 
1.5.1 ART regimens 
The discovery of drugs that suppress the HIV-1 replication has transformed the infection 
from a fatal to a chronic manageable disease [106]. Currently, there are 27 anti-HIV-1 drugs 
approved for clinical use and classified into six drug classes (NRTIs, NNRTIs, PIs, INSTIs, 
fusion inhibitor,  CCR5-antagonist) among which 16 are more commonly used [107]: 
nucleoside or nucleotide analogue reverse transcriptase inhibitors (NRTIs) was the first drug 
class discovered and inhibits reverse transcription. The NRTIs mimic and compete with 
natural nucleotide substrates of RT and inhibit viral DNA synthesis. Commonly used NRTIs 
in RLS include: lamivudine (3TC), emitricitabine (FTC), stavudine (d4T), zidovudine (AZT), 
and tenofovir disoprovil fumarate (TDF) [108, 109]. Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs) also inhibit reverse transcription by allosteric binding of RT in non-
competitive manner resulting in conformational changes and deactivation. Among the 
NNRTIs, efavirenz (EFV), and nevirapine (NVP), are the most commonly used in RLS, 
being the main and alternative first line agents, respectively [107, 110]. Protease inhibitors 
(PIs) inhibit Gag and Gag-Pol polyprotein cleavage by the protease enzyme. This class of 
drug was for many years part of the standard first line ART in high-income countries while it 
is reserved for second line in RLS where either lopinavir (LPV), atazanavir (ATV), or 
darunavir are used [111, 112]. Integrase strand transfer inhibitors (INSTIs) inhibit specifically 
the strand-transfer activity of the INT enzyme. Currently there are four INSTIs approved for 
HIV-1 treatment, namely raltegravir, elvitegravir, dolutegravir (DTG) and bictegravir (BIC) 
[113] and,  the DTG is considered nowadays as a drug of choice among initial ART regimens 
because of the high efficacy and limited toxicity [114]. In 2017 World Health Organization 
(WHO) recommended that all first-line regimens should include the INSTI DTG if the 
pretreatment drug resistance (PDR) rate is >10% in a geographical region [115]. The only 
approved fusion inhibitor enfuvirtide T-20 is a gp41 inhibitor that binds to gp41 and inhibits 
host-viral membrane fusion [116]. It is indicated for treatment of therapy experienced patients 
not responding to other drugs despite ongoing therapy but is today hardly used [117]. The last 
drug class, CCR5-antagonists, targets the CCR5 receptor and specifically blocks the 
attachment of viruses which use CCR5 as a co-receptor for entry but does not affect viruses 
that use CXCR4 [108]. Maraviroc (MVC) is the only one approved in this class [116] and is 
used as an option for treatment of R5-tropic virus infection in high resource countries [118]. 
During the development of this PhD project, maraviroc’s rollout to RLS was expected and 
thus study on the utility of this agent for HIV-1C was included as part of the project. Co-
receptor tropism testing in connection with using this agent is discussed below. 
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In high-income countries, first-line standard ART combines two NRTIs with one of NNRTI, 
one boosted PI or one INI [119]. Subsequent regimen decisions are guided by routine VL 
testing, drug resistance monitoring and/or tolerability [120]. Since a few years the use of 
combination ART consisting of 2NRTI and DTG has increased substantially. In contrast, 
neither routine VL testing, drug resistance testing, tropism testing are usually available in 
RLS where non-subtype-B HIV-1 predominates. Also several drug options are lacking. Thus, 
WHO has until recently recommended a public health approach of ART using standardized 
first-line (NNRTI+ dual NRTI) and second line (boosted PI (LPV or ATV) + dual NRTI) 
regimens in RLS [112, 120]. The new WHO guidelines from 2017 recommend the use of the 
second generation INSTIs- DTG combined with 2 NRTIs as an alternative first line in RLS 
[115]. Clinical criteria and CD4+ count (see below for detailed discussion of CD4) are the 
main strategy for monitoring  of ART in these setting  which  could result in switching to 
second-line therapy which might not be necessary as well as continuing on an already failed 
first-line ART, and consequently it might lead to an increased number of resistance mutations 
[121]. 
In Ethiopia, first line ART consisted for many years of two nucleoside analogues (AZT, 3TC, 
d4T and/or TDF) combined with either EFV or NVP [122, 123]. However in the last years 
d4T is avoided due to severe side effects. Patients are followed up on a monthly basis in the 
first three or more months of ART, until they show clinical stability and good adherence. 
Afterwards, the follow-up is scheduled on every three months basis, or as clinically required. 
1.5.2 CD4+ cell count 
The standard level for treatment initiation was recently updated to any CD4+ cell count 
instead of the previous of 500 cells/μl; this recommendation will eliminate CD4 count as a 
criteria for ART enrolment and allow initiation of ART for all people living with HIV [112, 
124], while giving priority for those with CD4 cell count below 350 cells/μl. However, CD4+ 
count level is also useful for treatment efficacy monitoring in a setting lacking VL 
measurement. Flow cytometry counting with fluorescently labelled monoclonal antibodies is 
the conventional and most widely accepted choice for enumeration [124, 125] with the only 
challenge coming from the large machinery and high instrumental cost, which make its use 
difficult in RLSs.   
National guidelines recommended CD4 monitoring of ART in Ethiopia every six months 
after initiation of therapy or when it deems necessary [122]. As availability of infrastructure 
and instruments is limited to ART centers located in urban areas, implementation has been 
attempted by establishing sample referral network where ART centers lacking CD4 
enumeration instrument are linked to the nearby center with flow cytometry instrument.  
However it should be noted that there are bottlenecks in the implementation such as poor 
reagent supply chain, frequent breakage of equipment and, shortage of trained manpower and 
parts to maintain the instruments. Most recent Ethiopian guidelines (2017) recommend CD4 
count assessment for patients on ART when indicated only [123]. 
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1.5.3 HIV Viral Load 
In high income countries, VL measurement is the gold standard for monitoring patients on 
ART [126]. VL monitoring is associated with favourable outcome compared to CD4 based 
monitoring to have a better early detection of treatment failure in RLS [127]. The most 
widely used method so far is the nucleic acid based assay. However, this assay is expensive 
and unsustainable, and is conducted centrally and occasionally in most of RLS as it requires a 
sophisticated laboratory infrastructure, highly skilled manpower and well established logistics 
[128].  Nevertheless, WHO hopes for availability of new point of care viral load 
measurement technologies and thus new WHO guidelines recommend routine VL monitoring 
at six month, 12 months, and every 12 months thereafter given that the patient remains 
clinically stable [112, 128]. 
VL monitoring facilities in Ethiopia are established at regional level where the regional 
laboratories are linked to referral hospitals in the region. Patients suspected of treatment 
failure are invited to visit referral hospitals where they are evaluated and sampled for VL 
measurement [129]. Samples are then transported to the regional laboratory where VL 
measurement is performed periodically, with turnaround time of several months. 
Furthermore, such approach is cumbersome given the rapid rollout of ART to remote areas of 
the country, with lack of infrastructure and resources. Thus, gaps in monitoring approaches 
might facilitate unnoticed development and spread of drug resistance to commonly used ART 
regimens, a scenario that necessitates drug resistance testing. 
1.5.4 HIV-1 drug resistance testing 
Assays for HIV-1 drug resistance are either phenotypic or genotypic. 
Phenotypic assays measure the drug concentration that inhibits viral replication by 50% 
(IC50) in cell cultures [130] compared to wild type control strains. Usually it requires 
production of recombinant virus by cloning of PCR amplified segment of HIV-1 gene of 
interest from a patient sample into a backbone of wild type clone lacking the gene of interest 
which is resource and labour-intensive as well as time-consuming. Thus, it is mostly reserved 
for drug development and resistance research [107]. Therefore, genotypic assays have 
become the preferred method over phenotypic assays.  
Genotypic drug resistance testing depends on the detection of known drug-resistance 
mutations (DRMs), usually by PBSS of the pol region covering the 297 nucleotides of PR, 
and the 5′ polymerase coding region of RT (amino acid positions 40–240), where most of 
NRTI- and NNRTI-resistance mutations are found [130]. DRMs are usually unfit under 
natural conditions and arise as a result of selective drug pressure under suboptimal drug 
concentration. A mutation could be a primary directly reducing susceptibility to a given drug 
or accessory which enhance fitness of primary resistance variants or further reduce 
susceptibility [107].  
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Due to the varying impact and interactions among mutations, the genotypic method relies on 
the correct interpretation of the mutations detected. Among the several interpretation 
algorithms developed, Stanford HIV database is the most widely used one and provides 
scores for the mutations [131], which will be converted  to various levels of susceptibility 
based on literature and expert's opinion [130, 131]. These algorithms were developed based 
on HIV-1B data. A recent study assessed the concordance between three interpretation 
methods and found significant discordances including subtype related differences, calling for 
a critical need for further development and improvement of the existing interpretation 
algorithms as ART and HIV genotyping becomes available in many African and Asian 
countries in connection with aiming at the new WHO 90-90-90 goals [132]. A version of 
Stanford HIVdb, calibrated population resistance tool (CPR), provides a standard list of 
surveillance drug resistance mutations (sDRMs) as indicator of transmitted drug resistance 
(TDR) which is based on the criteria that: i) the mutation should be recognized as causing or 
contributing to resistance; ii) being non-polymorphic and not appearing in polymorphic 
positions, and iii) applicable to eight common HIV-1 subtypes. This list is based on WHO’s 
2009 sDRM list [133]. The CPR tool was used to identify pre-treatment drug resistance 
mutations in this PhD project. There is no recommendation yet to use drug resistance testing 
as a monitoring tool of individuals on  ART in RLS [134]; its availability is limited to 
regional or national reference laboratories due to its very high cost.  
1.5.5 HIV-1 tropism testing  
As mentioned in the tropism section above, HIV-1 tropism is related to disease progression 
but it has also been claimed to have an impact on treatment outcome of standard ART. 
Moreover, it affects response to the only currently licensed entry inhibitor targeting CCR5, 
maraviroc, where presence of X4-tropic viruses must be excluded prior to treatment with this 
drug. Both genotypic as well as phenotypic methods can be used to test for HIV-1 tropism. 
1.5.5.1  Genotypic tropism testing 
Genotypic tropism testing (GTT) offers a quicker and less expensive option and generally 
involve nucleotide sequencing of the gp120 third variable (V3) loop which is characterized 
by high variability including insertions, deletions and mutations [135]. Studies have shown 
that even a single change among the V3 loop amino acids could result in a tropism shift [136] 
and X4-tropic sequence characteristics include higher charge, increased genetic diversity and 
sequence length [135, 137]. These characteristics of X4-tropic sequences allow genotypic 
algorithms to draw sequence features for prediction of co-receptor usage [135]. The simplest 
prediction model has been the 11/25 charge rule where positively-charged amino acid 
residues at V3 loop codons 11 and 25 such as arginine (R) and lysine (K) have been strongly 
associated with a CXCR4-tropic phenotype [138]. However, positions outside 11 and 25 are 
also known to be associated with tropism [139] and as a result, bioinformatics approaches are 
required. Raymond et al developed a simple genotypic prediction combining 11/25 rule and 
the net V3 charge [140, 141]. There are also several bioinformatics based algorithms 
developed including position specific scoring matrix (PSSM) [142], geno2pheno (G2P) 
  13 
[143], and the most recent, PhenoSeq [144]. These algorithms were designed to infer 
phenotypic assay results from V3 loop nucleotide sequences using statistical techniques to 
weigh the prevalence of amino acid variants in each position. A score that estimates the 
probability of being associated with R5 phenotype is generated for amino acid variants in the 
V3 loop. In the case of G2P, this score is further transformed into a predicted false positive 
rate (FPR) [145] which indicates likelihood of falsely predicting a given V3 loop sequence as 
X4 using. To convert the spectrums of likelihood scores into a binary inference of tropism 
(i.e. “R5” or “non-R5”), appropriate cut-offs should be established. For instance, a G2P cut-
off of 5.0% FPR is 92.6% specific and 67.4% sensitive against the original Trofile assay for 
detecting non-R5 [146]. As mentioned above, some clinical parameters, like CD4+ count and 
VL, are shown to be associated with co-receptor usage in chronic HIV infection. A clinical 
version of G2P has been developed and includes clinical parameters such as CD4 count and 
VL to improve the prediction [147].   
Yet, there is a speculation that genetic determinants outside the V3 loop of HIV-1 env may 
affect the ability of GTT tools to precisely predict tropism [148-151]. Moreover, discordant 
prediction by genotypic algorithms arises because of different statistical models employed, 
the way of handling changes in the loop like insertions, deletions, and ambiguous amino-acid 
positions [152]. Also, GTT methods do not allow discriminating between pure X4 and 
dual/mixed R5X4 viruses [153]. 
Performance of the algorithms is influenced by the training data including the subtype of the 
V3 sequence used and most GTT methods have been developed using genetic data from 
HIV-1B [154] posing a question as to whether they have capacity to predict tropism in non-B 
HIV-1 subtypes. Studies that attempted to validate these utilities in different clinical setups 
and subtypes have shown a limited sensitivity of detecting X4-tropic strains as well as 
differences between subtypes [155] using phenotypic assays as gold standard even though 
95% specificity of G2P has been reported for predicting X4-tropism in HIV-1C [156]. One 
recent study using a phenotypic assay reported an overestimation of X4 virus by G2P fpr10% 
when compared with PSSM as well as commercial and non-commercial phenotypic assays in 
a cohort of acutely HIV-1 infected patients [152]. Thus, despite their ease of use and lesser 
expense, there are unresolved issues with GTT methods and hence, calls for more studies 
which evaluate further the utility of tropism tests in different subtypes and settings. The 
abovementioned genotypic tools were used in this thesis to predict tropism in HIV-1C and 
impact of the predicted tropism on the outcome of standard ART. 
1.5.5.2 Phenotypic tropism assays 
The oldest phenotypic assay to assess HIV tropism was the MT-2 assay which, based on the 
ability to induce formation of multinucleated giant cells, “syncytia”, classified HIV into 
syncytium-inducing (SI) or non-syncytium-inducing (NSI) phenotypes [157]. NSI viruses are 
generally associated with CCR5 co-receptor usage, whereas SI viruses are generally 
associated with CXCR4 usage [158]. Over the last decade, various commercial phenotypic 
assays have been developed to measure tropism based on recombinant viruses, such as the 
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Enhanced-Sensitivity-Trofile-Assay (ESTA) [159], the Virco phenotypic test [160], the 
Phenoscript test [161] and the Toulouse Tropism Test [153]. Non-commercial assays utilizing 
recombinant particles or pseudovirions have been also shown to be good in measuring 
tropism [162-164] and has been claimed to even be able of differentiating between the dual-
tropic viruses and a mixture containing both R5- and X4-tropic strains [165], which is one of 
the shortcomings of commercial assays. However, factors including higher cost and longer 
turn-around time made their usage in clinical setup limited although the non-commercial 
assays are relatively less expensive. In this thesis, an in house phenotypic assay was 
employed and compared with predictions by genotypic methods. 
1.6 OUTCOMES OF ART 
According to the US department of health, the goal of ART is “to achieve maximum and 
durable suppression of plasma HIV RNA; restoring and preserving immunological functions; 
reducing HIV-related comorbidities and prolonging and improving quality of life; and 
preventing transmission of the virus” [166]. Viral suppression indicates treatment success and 
lesser potential of transmitting the virus. 
1.6.1 Definitions 
According to WHO guidelines for RLS (2016), ART failure in adults and adolescents may be 
defined as clinical, immunological or virological.  
Clinical failure is defined as ‘‘a new or recurrent clinical event indicating severe 
immunodeficiency (WHO clinical stage 4 conditions) after six months of effective treatment. 
The condition must be differentiated from immune reconstitution syndrome (IRIS), which 
occurs after initiation of ART’’ [112, 166]. 
Immunological failure is a situation when ‘’CD4 count falls to or below the baseline or 
persistent CD4 levels below 100 cells/mm. However, the event should be without 
concomitant or recent infection which may cause a transient decline in the CD4 cell count’’.  
Virological failure is defined by a ‘’persistently detectable viral load exceeding 1000 
copies/mL (that is, two consecutive VL measurements within a three-month interval with 
adherence support between measurements) after at least six months of starting a new ART 
regimen’’ [112]. 
1.7 THE ADVANCED CLINICAL MONITORING OF ART (ACM) PROJECT IN 
ETHIOPIA 
Incepted in 2005 as a compendium of 10 national (Federal Ministry of Health, FHAPCO, 
EHNRI, and seven hospitals affiliated with medical universities in Ethiopia) and two 
international institutions (Johns Hopkins University – Bloomberg School of Public Health 
(JHU) and the United States Centers for Disease Control & Prevention (CDC), the ACM 
project in Ethiopia is a longitudinal cohort study designed to evaluate the effectiveness of the 
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national free ART program at the participating hospitals in diverse geographical locations 
(figure 4). 
Established by considering age during the consent process, the ACM included an adult and 
adolescent cohort (age >= 14years), and a paediatric cohort (age < 14 years), each consisting 
of a database (retrospective data before enrolment) and repository (prospective data at 
enrolment and thereafter) sub cohorts. For the adult and adolescent sub-cohort, plasma 
samples were collected every six months at each study site, stored temporarily at -20
o
C, and 
transported regularly to EHNRI for storage at -80
 o
C [167]. From January 1, 2005 to August 
31, 2013, a total of 4339 participants were enrolled to the project among which 982 
participants were enrolled from the multi-site adult and adolescent repository cohort between 
September 2009 and August 31, 2013 [167].  
 
Figure 4. Study sites of the Advanced Clinical Monitoring (ACM) cohort: The Tikur Anbessa hospital is 
situated in the capital city, Addis Ababa. The clinical caring for the Armed Forces, the “Mobile Group”, is also 
situated in Addis Ababa. 
Although ACM project was terminated thereafter because of the discontinuation of funding 
from the donor (CDC), it is among the larger cohort studies in Africa, which included more 
than 4,000 patients. Such cohort studies have been critical in nourishing understanding of 
HIV and effectiveness of ART in a real-world setting. This thesis took an advantage of such  
research platform created by ACM and accessed adult and adolescent repository cohort 
specimens as well as associated data to achieve the aims which are described below.  
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2 OBJECTIVE AND AIMS 
2.1 OBJECTIVE OF THE THESIS 
Overall objective of the thesis was to investigate the molecular characteristics of HIV-1C and 
the impact on first line antiretroviral therapy (ART) outcome in Ethiopia. 
2.2 SPECIFIC AIMS 
Paper I 
To assess the molecular epidemiology of the Ethiopian HIV-1C epidemic in different 
geographic regions of Ethiopia and the trend of viral tropism over the last two decades. 
Paper II 
To investigate the utility of genotypic co-receptor tropism prediction tools and evaluate the 
impact of the predicted viral co-receptor tropism on the outcome of non-maraviroc containing 
standard first line ART in Ethiopia. 
Paper III 
To analyse the phenotypic tropism of HIV-1CEth strains in comparison with the genotypic  
prediction by five bioinformatics tools and compare the in vitro sensitivity of pure R5-tropic 
and dual-tropic HIV-1CEth strains for the co-receptor antagonist maraviroc. 
Paper IV 
To assess the prevalence of surveillance drug resistance mutations (sDRM) to reverse 
transcriptase- and protease-inhibitors by population-based Sanger sequencing as compared to 
next-generation sequencing and evaluate their impact on first line ART outcome as well as 
analyse the occurrence of DRM by NGS to the novel category of integrase strand inhibitors. 
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3 MATERIAL AND METHODS 
3.1 STUDY SUBJECTS 
The samples and data used in this thesis have been mainly obtained from HIV-1 infected 
patients recruited to the ACM project, both at baseline (treatment-naïve) and/or at follow-up 
points- months six and twelve (treatment-experienced). Through October 2009 to December 
2011, a total of 874 ART naïve patients were recruited to the ACM repository sub cohort, and 
started ART, as per the national guideline [122]. The subjects were from seven universities 
[167, 168] distributed geographically all over the country (figure 4): Tikur Anbessa 
Specialized Hospital in Addis Ababa- Central region; Gondar– Northwest; Jimma– West; 
Mekelle– North; Harrar– East; Hawassa– South; the Army unit providing service to mobile 
military staff and family, which is located in Addis Ababa (Figure 4). Plasma samples were 
temporarily stored at -20
o
C and transported thereafter to the central laboratory of the 
Ethiopian Health and Nutrition research institute (EHNRI) and stored at -80
o
C. Historical 
sequence data were obtained from online databases for comparative analysis employed in 
some papers as described below. 
In Paper I and II, plasma samples were obtained from 420 treatment-naïve patients of whom 
41 also contributed with plasma while failing ART. In addition, a total of 387 historical V3 
loop sequences from HIV-1CETH dated from 1984-2003 were downloaded from the Los 
Alamos database (accessed on 23
th
 January 2015) for Paper I. 
For Paper III, plasma samples were obtained from 58 treatment-naïve subjects, who were 
selected based on a discordant co-receptor usage (n=42), a concordant CCR5 co-receptor 
usage (n=10) or a concordant CXCR4 co-receptor usage (n=6), as predicted by the five GTT 
tools in paper II.  
For Paper IV, the study was conducted on 490 subjects (age ≥14 years), randomly selected 
after stratifying by study sites (70 from each site). In addition, baseline samples of 109 
patients with virologic treatment failure (n=71) or with virologic suppression (n=38) patients 
were analysed by NGS. 
3.2 CD4+ CELL COUNT AND VIRAL LOAD MEASUREMENT 
CD4+ count was determined from patients’ uncoagulated whole blood at laboratories within 
the participating health facilities using BD FACSCalibur machines (Becton Dickinson, San 
Jose, USA). Plasma VL was measured in the national reference laboratory at the Ethiopian 
Public Health Institute (EPHI) using NucliSENS easyQ® HIV-1 Nucleic Acid Sequence-
Based-Amplification (NASBA) assay (BioMérieux Diagnostics). 
3.3 RNA EXTRACTION 
A summary of the experiments in the thesis is depicted in figure5 below. HIV-1 RNA was 
extracted from plasma by QIAamp Viral RNA kit (Qiagen, Hilden, Germany) 140ul of 
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plasma was used for patients having VL> 10,000 copies/ml, while 1ml of plasma was 
centrifuged at high speed to concentrate the virus for patients with VL< 10,000 copies/ml. 
 
Figure 5: Summary of experiments in the thesis. 
3.4 REVERSE TRANSCRIPTION AND NESTED PCR 
In Paper I, II and IV cDNA was synthesized from extracted RNA using RevertAid H-minus 
reagents (Life technologies, UK) followed by subsequent amplification and nesting in two 
rounds by using the Applied Biosystem PCR system reagents and Taq-polymerase enzyme.  
In Paper III cDNA was synthesized from extracted RNA using using SuperScript® III 
Reverse Transcriptase (Invitrogen/Life Technology) with Oligo (dT)18 primer (Thermo 
Scientific) followed by subsequent amplification and nesting using  KAPA HiFi HotStart 
ReadyMix PCR kit (Kapa Biosystems, US). Table 1 below lists primers used for 
amplification and sequencing. 
3.5 DNA PURIFICATION AND SEQUENCING 
For Paper I-III, the amplicons were purified by QIAquick kit (Qiagen) and sequenced in 
automated sequencer (ABI 3130xl Genetic Analyser, Applied Biosystems). Sequences were 
aligned, edited, and analysed by the BioEdit software v. 7.0.9.  The V3 loop sequence was 
derived by a gene cutter program (http://www.hiv.lanl.gov/content/sequence 
/GENE_CUTTER/cutter.html).  
In Paper IV, the amplified fragments were purified (QIAquick PCR Purification Kit, Qiagen, 
Hilden, Germany) and sequenced with PCR primers JA204F-C and JA205R-C plus PR2R 
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and RT07. Sequences were aligned, edited and analysed using the BioEdit software version 
7.2.6.1 (http://www.mbio.ncsu.edu/bioedit/bioedit.html) 
Table 1: List of primers used for amplification and sequencing in each constituent paper. 
Primer ID Sequence  HXB2 
Position 
Used for Used in paper 
ED5-1F 5'-ATGGGATCAAAGCCTAAAGCCATGTG-3' 6556–6581 1st PCR Paper I-II 
ED12-1R 5'-AGTGCTTCCTGCTGCTCCCAAGAACCCAAG-3' 7822–7792 1st PCR Paper I-II 
ES7-2F 5'-TTRTTAAATGGTAGTATAGC-3' 7001–7020 2nd PCR, sequencing Paper I-II 
ES8-2R 5'-CACTTCTCCAATTGTCCCTCA-3' 7667–7647 2nd PCR, sequencing Paper I-II 
5550F 5’-AGARGAYAGATGGAACAAGCCCCAG-3’ 5550–5574 1st PCR Paper III 
9555R 5’-TCTACCTAGAGAGACCCAGTACA-3’  9555–9533 1st PCR Paper III 
6433F 5’- CYACCAACGCGTGTGTACCCACAGA-3’  6433–6457 2nd PCR, sequencing Paper III 
8329R 5’-CCCTGCCGGCCTCTATTYAYTATAGAAA-3’ 8356 – 8329 2nd PCR Paper III 
JA203F-C   5’-GAA AGA CTG TAC TGA GAG ACA GGC-3’ 2058-2081 1st PCR Paper IV 
JA204F-C 5’-TTCAGAGCAGACCAGAGCCAACAG-3’ 2135-2158 2nd PCR, sequencing Paper IV 
JA205R-C 5’-TTTTCCCACTAACTTCTGTATATC-3’ 3338-3315 2nd PCR, sequencing Paper IV 
JA206R-C   5’-TTA ATC CCT GGG TAA ATC TGA CTT-3’ 3373-3350 1st PCR Paper IV 
RT07 5’-AAGCCAGGAATGGATGGCCCA-3’ 2586–2606 Sequencing Paper IV 
PR2R 5’-GGATTTTCAGGCCCAATTTTTG-3’ 2691- 2713 Sequencing Paper IV 
3.6 SUBTYPING AND PHYLOGENETIC ANALYSIS 
Subtyping was done by the REGA subtyping tool v2.0 [169], the RIP 3.0  
(http://www.hiv.lanl.gov/content/sequence /RIP/RIP.html, and the COMET HIV [170]. 
Maximum likelihood phylogenetic analysis was performed using Molecular Evolutionary 
Generics Analysis version 7.0 (MEGA 7) software.  
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3.7 CELL CULTURE 
TZM-bl, 293T, GHOST (GFP-expressing Human Osteo Sarcoma T4) (3) CXCR4+, and 
GHOST (3) CCR5+ Cells (Hi-5) cells were used in Paper III. TZM-bl and 293T cells were 
propagated in Dulbecco's Modified Eagle Medium (DMEM) (Sigma, US), supplemented 
with 10% Fetal Bovine Serum (FBS) and 2mM L-glutamine while GHOST cells were 
propagated in high glucose DMEM supplemented with 10% FBS.  
3.8 CLONING AND RECOMBINANT VIRUS PRODUCTION 
In Paper III, QIAquickGel Extraction Kit (Qiagen, USA) was used for gel purification of 
PCR fragments and the purified products were cloned in pMN-K7-Luc-IRESs-NefΔgp120 
plasmid following digestion with restriction enzymes NgoMIV and MluI-HF (New England 
Biolab, US) , ligation with T4 DNA ligase, transformation into competent 
DH5alpha E.coli cells (Invitrogen, Life Technologies, MA, USA) and subsequent colony 
screening + plasmid isolation. Recombinant viruses were produced by transfecting the 
plasmids using FuGENE® HD Transfection Reagent (Promega, US) in 293T cell line, 
incubation for 48 hours and lysing the cells followed by centrifugation to get cell free 
supernatants and stored at -80
0
C if not used immediately. Infectivity of the recombinant 
viruses generated from individual clones was tested by infecting 10
4
 TZM-bl cells with Env-
recombinant viruses in DMEM containing 20ug/ml of DEAE-dextran and cultured for 48 
hours, after which luciferase activity was measured using the Luciferase Bright Glo™ assay 
system (PROMEGA, USA). All infections were done in triplicate. Recombinant viruses were 
considered infective if the luciferase read were no less than 2.5x the background as described 
previously for TZM-bl cells [171]. 
3.9 TROPISM TESTING 
Both genotypic (GTT) and phenotypic (PTT) methods were used to determine viral tropism 
in this thesis as described below. 
3.9.1 Genotypic methods  
In Paper I G2P clonal and clinical algorithms were used for prediction of tropism based on 
the V3 loop while in Paper II three additional bioinformatics tools- PhenoSeq-C, C-PSSM 
and Raymond’s algorithm - were used for prediction of tropism based on the V3 loop. For 
GTT of cloned env in Paper III, same tools as in paper II were employed. 
3.9.2 Phenotypic method  
For phenotypic tropism testing in Paper III, GHOST  indicator cells- GHOST (3) CXCR4+, 
and GHOST (3) CCR5+ Cells (Hi-5) were infected with viruses generated from individual 
clones in DMEM containing 10ug/ml polybrene and luciferase activity was measured using 
the Promega Luciferase assay kit as described above under recombinant virus production. 
Viruses were interpreted as R5 or X4-tropic if the luciferase read was more than 2.5x the 
background and dual tropic if luciferase read more than 2.5x in both GHOST cell lines. 
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3.10 MARAVIROC DRUG SENSITIVITY ASSAY 
TCID50 was determined for each recombinant virus as described elsewhere,[172] in 
hexaplicate, and using Spearman Karber formula [173]. The drug sensitivity of the 
recombinant viruses was measured by adding serial dilutions of drug spanning 10 µM to 
1x10
-6
 µM, in 96-well plates containing TZM-bl cells in complete DMEM media followed by 
infection with reference virus (R5-tropic, MJ4 and X4-tropic, NL4-3) or the patient derived 
recombinant viruses, at a multiplicity of infection (MOI) of 0.01 IU/cells using 10µg/ml of 
DEAE-dextran and incubated for 48 hours. Luciferase activity was measured as described 
above. Dose response data was analysed using GraphPad Prism version 7.00 for Windows, 
GraphPad Software, La Jolla California USA. 
3.11 GENOTYPIC DRUG RESISTANCE TESTING (PAPER IV) 
Sequences generated from PBSS were aligned, edited and analysed using the BioEdit 
software version 7.2.6.1 (http://www.mbio.ncsu.edu/bioedit/bioedit.html). Primary DRM 
were identified using calibrated population resistance tool (http://cpr.stanford.edu/cpr.cgi) at 
Stanford HIVDR Database. DRMs associated with NRTI-, NNRTI-, and PI- drug classes are 
considered in this assay. For NGS, Gag-pol fragment (HXB2: 790 – 5096) was amplified, gel 
purified, and fragmented on the Coveris S200 followed by library preparation using 
NEBNext UltraTM DNA library Prep Kit. Forty-eight libraries were then pooled at 
equimolar (10nM each) and run on Illumina HiSeq 2500. The FASTQ file was demultiplexed 
and the consensus sequence was created for each sample followed by realignment again with 
the consensus sequence as input. The variant calling was performed at amino acid (AA) level. 
Only AA covering 5000X per position was considered quality passed. Based on the error 
calculation generated by PCR and NGS, any mutation >1% was considered. WHO list of 
DRM for surveillance of TDR was used to interpret sDRM for NRTIs, NNRTIs, PIs, and the 
Stanford drug resistance summaries for INSTIs (hivdb.stanford.edu). 
3.12 STATISTICAL METHODS AND APPROACHES USED  
We used descriptive statistics (mean, median, standard deviation, and percentiles for 
numerical variables, frequencies and percentages for categorical variables) to summarize 
sociodemographic, clinical, immunological, and virological parameters. Chi-square test or 
Fisher’s Exact Test were used to test differences between categorical variables. Differences 
of numerical variables between two or more categories were assessed using Independent t-
test, Mann-Whitney, Anova and Kruskal-Wallis test.  
In Paper I & II, we used both intention-to-treat (ITT) and on-treatment (OT) analysis to 
assess treatment outcomes. ART failure was defined as either detectable VL (>1000 
copies/ml), died or LTFU in the ITT analysis while only patients having VL data at a given 
follow up time point were included In the OT analysis. Logistic regression models were used 
for the multivariable analysis of virological responses to compare differences between R5 and 
X4 infected patients as tropism predicted by different methods, adjusting by age and gender, 
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baseline CD4+ T-cell count and VL. Results from regression models were presented using 
Odds Ratios (OR), 95% Confidence interval and p-values. 
In Paper III, sensitivity, specificity, positive predictive value (PPV), negative predictive 
value (NPV) and Cohen Kappa coefficient (k) were calculated for the results obtained by the 
GTT methods using the in house phenotypic assay as a gold standard.  
In Paper IV, the impact of pretreatment sDRM (RTI, PI) detected by PBSS and NGS assays 
on virologic treatment outcome at month six and 12 was assessed by using a multivariable 
logistic regression model testing for different confounding factors including gender, age, 
WHO clinical stage, functional status, TB, CD4 cell count, baseline VL, and NRTI regimens.  
In all of the papers, p-value <0.05 was considered statistically significant. Data analysis was 
performed using STATA software 14 (Stata Corp. College Station, Texas, USA). 
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4 RESULTS 
The overall aim of the thesis was to investigate the molecular characteristics of HIV-1C and 
its impact on first line antiretroviral therapy (ART) outcome in Ethiopia. We described the 
env (Paper I-III) and pol regions (Paper IV) using PBSS, NGS, as well as the functional 
characteristics of the env in a cloning based phenotypic assay, as described in the methods 
section, to characterize the virus and correlate with ART outcome. In this section, main 
results from the studies will be presented and summarized. 
4.1 PAPER I 
This paper described our attempt to analyse, using the countywide multi-site cohort, the 
current status of the Ethiopian HIV-1 epidemic which was the first HIV-1C epidemic 
reported globally and described by our group in 1980’s. From 420 patients included in this 
study, sequencing was successful in 352 of the patients. Furthermore, 387 historical sequence 
data (dated 1984-2003) was included for comparison. 
Subtyping and genotypic tropism prediction 
Using the three subtyping tools, HIV-1C was found in 350 (99.4%) and A1 in two (0.6%) of 
the 352 patients. In addition to determining the subtype, we also analysed the predicted 
genotypic tropism of the 352 baseline V3-nucleotide sequences using the G2P bioinformatics 
tools. The G2P clinical model fpr10%, predicted the following: R5 - 285 (81.0%); X4 - 60 
(17.0%); mixed (R5/X4) 7 (2.0%) (Figure 2a, Paper I). The G2P clonal model predicted: R5 - 
291 (82.7%); X4 - 50 (14.2%); R5/X4 - 11 (3.1%) (Figure 2b, Paper I).  
Altogether, 266 (75.6%) of the 352 predictions were concordant between the two models at 
fpr10%. No association was found between the predicted baseline tropism and age, gender or 
VL. There was no difference in occurrence of R5-virus across the geographical regions.  
Temporal trend of viral tropism (1984-2011) 
We assessed the temporal trend of viral tropism during the last two decades using 387 
historical V3 loop sequences from HIV-1CETH dated from 1984-2003 (1984-1993: n= 91; 
1994-2003: n= 296), and sequences from our study (2009-2011). The proportion of X4-
tropic/ mixed (R5/X4)-tropic virus increased from 5.6% (1984-1993), 7.1% (1994-2003), to 
17.3% (2009-2011) (p<0.001) (Figure 6).  
4.2 PAPER II 
In Paper II, we analysed the sequences from Paper I further by employing more 
bioinformatics tools as there was a large discordance in tropism prediction between the 
methods used in Paper I. The aim was to investigate the utility of different bioinformatics 
prediction tools and evaluate impact of the predicted viral co-receptor tropism on the outcome 
of standard first line ART.  
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Figure 6. Temporal trend in the proportion of X4 tropic virus among Ethiopian HIV-1 isolates by Geno2Pheno 
clonal model (1984-2011). 
R5 prediction at baseline  
The proportion of patients predicted to harbour R5-tropic virus varied between the methods 
by 12.5%, (90.6%, Raymond’s Vs 78.1%, PhenoSeq-C) as shown in Table 1 of Paper II. 
Altogether, only 205 (58.2%) of the predictions were concordant by the five tools used (Table 
2 of Paper II).  
Impact of baseline tropism on ART outcome 
We assessed whether tropism as predicted by each method at baseline had an impact on 
treatment outcome both by OT and ITT analysis (as shown in table 3 and 4 of Paper II 
respectively). No difference was observed between R5 and X4 infected patients at months six 
and 12 in multivariable OT analysis. Tropism as predicted by C-PSSM had an impact on 
month 12  in multivariable ITT analysis, with patients harbouring R5 tropic virus at baseline  
having 2.47 higher odds to achieve VL suppression compared to those with X4 virus (p=0.04, 
OR 2.47, 95% CI 1.05-5.79) (Table 5 in Paper II). 
Tropism switch at months six and 12  
At month six, virological failure occurred in 37 of the 352 patients and seven additional 
patients who were included only for the study of co-receptor switch. Paired plasma samples 
were available for 41 patients out of which V3 sequencing was successful in 34 patients. The 
most frequent rate of tropism switch (7/34; 20.6%) was predicted by C-PSSM (R5 to X4: 
4/26; X4 to R5: 3/8; p= 0.017), while 4/34 strains switched each (two R5 to X4 and two X4 
to R5) as predicted by PhenoSeq-C and G2P clonal tools, and 4/34 strain switched (R5 to X4: 
3/30; X4 to R5: 1/4) as predicted by Raymond’s algorithm.  
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At month 12, virological failure occurred in 22 subjects in whom V3 sequencing was 
successful in 19. In most patients, tropism predicted at baseline was maintained at the month 
12 prediction.   
4.3 PAPER III  
As a high discordance was observed between the genotypic tropism prediction tools used in 
previous papers, we moved next to employ a phenotypic assay and compare with the 
predictions obtained by the GTT tools.   
Amplification of envgp120 was successful in 41 out of 58 (70.7%) and cloning in 35 of the 
41 (85.4%) patients from which one-hundred-twenty clones were screened and 79 (65%) 
were infectious. Tropism was determined for all of the infectious clones by the phenotypic 
assay, while V3 sequencing for GTT prediction was managed in 70 of the clones.  
Correlation between the phenotypic and genotypic methods  
By the phenotypic assay, 73 out of the 79 clones were R5 tropic, six were dual tropic, and 
none were pure X4 tropic. A genotypic prediction was obtained for 70 of the infectious 
clones. The phenotypic results were compared with the genotypic predictions, obtained with 
the five algorithms as shown in Table 2 of Paper III. Only 30 out of 64 (46.9%) pure 
phenotypic R5 clones were predicted as R5 by all GTT tools.  
Maraviroc drug sensitivity assay 
The EC50 values for the six dual tropic and the six R5 tropic viruses are shown in Table 3 
and the inhibition curves in Figure 1 of Paper III. There was no significant difference 
between the EC50 values of dual tropic and R5 tropic viruses (p=0.201).  
4.4 PAPER IV 
In order to explore a further region of the viral genome, we analysed the pol gene using PBSS 
and NGS with the aim to assess the prevalence of sDRM and evaluate their impact on first 
line ART outcome as well as analyse the occurrence of DRM by NGS to the novel category 
of integrase strand inhibitors.   
Baseline sDRM detected by PBSS and impact on treatment outcome 
At baseline, samples from 461 (94%) patients were successfully sequenced among which 
sDRM was detected in 18 (3.9%). (NRTI: n=9; NNRTI: n=7; PI: n=2) as shown in Figure 1 
and Table 2 of Paper IV.  
Patients harbouring baseline RTI-sDRM had higher odds of virologic failure considering both 
cut-offs (VL >150 copies/ml and VL> 1000 copies/ml) at month six (respectively OR (95% 
CI): 3.6 (1.2–11.1); and 9.00 (1.9–43.3)) as well as month 12 (respectively OR (95% CI): 6.5 
(2.1–20.3); and 7.4 (1.5–35.0) compared to those without RTI-sDRM. In the ITT analysis, 
patients harbouring RTI-sDRM showed a significantly higher odds of  treatment failure s at 
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month six, considering both viral failure cut-offs, than those without mutations (OR (95%CI): 
2.9 (1.0–7.9) and 3.8 (1.4–10.5), respectively).  
Baseline DRM detected by NGS  
Baseline sequences were obtained from all of the 109 patients included for NGS. DRM was 
detected in 28 patients (Table of paper IV). NGS detected RTI or PI sDRM more often 
(23.9%) than PBSS (6.4%) (p<0.0001). The NGS DRMs were found in 32.4% of the 71 
virologic failure patients at month six and/or 12 (>1000 copies/ml) (Table 3 of paper IV). In 
addition, INSTI DRMs-E138K, Q148R, Q148H, and T66I- were detected by NGS (Table 3 
of Paper IV).   
Impact of baseline DRM detected by NGS and correlation with PBSS 
NGS detected any RTI sDRM significantly more often (28.2%; 20/71) than PBSS (8.54%; 
6/71) (p=0.004) from baseline samples of ART failing patients (Table 3 Paper IV). Patients 
who failed ART with >150 copies/ml at month six and/or 12 had higher odds to have one or 
more NRTI, NNRTI and/or PI sDRM by NGS at baseline compared to the virologic 
suppressors (OR: 6.4; 95% CI: 1.6 – 26.4 adjusted for NRTI regimens and CD4 cell counts) 
(Table 3 Paper IV).  
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5 DISCUSSION 
HIV-1 is characterized by extensive genetic variability dependent on the location of the 
genome examined [13]. Such extensive genetic diversity of HIV-1 pose several challenges 
and implications for viral diagnosis [21], monitoring of the infection [22], development and 
patterns of drug resistance, disease progression [23], viral transmission, response to ART, and 
effective vaccine development [22, 24, 25].  HIV-1C is the most rapidly expanding subtype 
accounting for half of global HIV disease and nearly all infections in Ethiopia, Southern 
Africa and India which are the regions with the highest burden of HIV-1 infection. The 
molecular characteristics of this subtype success need to be explored to better understand 
such epidemic. 
In Paper I we attempted to describe the current status of the Ethiopian HIV epidemic which 
was the first HIV-1C epidemic reported globally.  Studies have since then consistently 
described the Ethiopian epidemic as predominated (97%-100%) by HIV-1C [27, 28, 174-
176]. As these studies were from limited regions of the country, and as various studies 
reported circulation of mixed subtypes in neighbouring countries including Djibouti (subtype 
C (66%), CRF02_AG (20%), B (8.5%), CRF02_AG/C (2.9%) and K/C (2.9%) [177], Sudan 
(subtype A (46%), C (33%) and D (21%), and northern Kenya (subtype A (50%), C (39%), 
and D (11%) [31], we hypothesized that regional differences may exist in the Ethiopian 
epidemic as a consequence or mirror of the situation in the neighbouring countries. We 
therefore investigated the subtype distribution in different geographical regions of Ethiopia.  
Results of our current study showed  that the Ethiopian HIV-1 epidemic is still 
monophylogenetic, exclusively dominated by HIV-1C, even though its first introduction was 
estimated to have been four decades back, around 1970 [178]. Our finding calls for further 
molecular and epidemiological studies to unravel such uniqueness despite changing 
epidemiology in the neighbouring countries. 
Viral tropism at baseline is of clinical relevance mainly in terms of disease progression and it 
has been claimed to impact standard first line ART [76, 79]. Again, the few old published 
studies from Ethiopia were conducted in limited geographical regions. Furthermore, recent 
studies from South Africa and India, countries where the epidemic is dominated by HIV-1C, 
have claimed an increase in the proportion of X4 viruses [66, 179]. Thus, we also analysed 
the temporal trend of co-receptor usage of HIV-CETH. We chose the G2P clonal and clinical 
models among several other tools available for genotypic tropism prediction (see below) as 
95% specificity of G2P have been reported for predicting X4-tropism in HIV-1C [156]. 
Moreover, it is the most widely used one and the European Guidelines recommend its use 
[180]. In our study, both tools predicted R5 tropism at a comparable frequency yet with much 
discrepancy between the predicted tropisms. Although such prediction discrepancy could be 
declared as a potential shortcoming which we tried to address further in Paper II, in general, 
our results described an epidemic dominated by R5 tropic virus and yet an increasing trend in 
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X4 tropic strains over the last decades, in agreement with other studies from South Africa and 
India where the epidemics are dominated by HIV-1C. However to investigate the prediction 
discrepancy by G2P models, we decided to analyse the sequences using more prediction tools 
in Paper II. 
Several genotypic bioinformatics algorithm based tools have been developed for prediction of 
tropism following the discovery of maraviroc, the only co-receptor antagonist licensed so far. 
These algorithms were designed to infer phenotypic results from V3 loop nucleotide 
sequences using statistical techniques to weigh the prevalence of amino acid variants in each 
position. A score that estimates the probability of being associated with R5 phenotype is 
generated for amino acid variants in the V3 loop. Performance of the GTT tools is influenced 
by the training data set employed  and most have been developed using  HIV-1 B data [154], 
although PhenoSeq-C and C-PSSM have been trained on HIV-1 C as well [142, 144]. In our 
study, each of the GTT  tool predicted a somewhat similar prevalence of R5-tropic viruses 
(ranging from 78.1-90.6%), in agreement with several previous studies which claimed a 
reliable performance of GTT tools [159, 181, 182], with no one clearly showing better 
performance than the other [183] although the comparison in these studies was with 
phenotypic assays. However, studies comparing concordance between GTT tools are limited. 
A large discordance between the five bioinformatics tools in our study could be explained by 
difference in statistical models employed by each tool, and different approaches to handle 
changes in a given V3 sequence [152]. By most of the prediction tools we used, there was a 
bidirectional switch of tropism at therapy failure, X4 to R5 being more frequent than R5 to 
X4. HIV-1 tropism switch under ART pressure in HIV1B have been reported in previous 
studies [73, 184, 185] with no dominance in either of the directions. Such viral switch during 
rebound seemingly occurring biased towards R5-virus and whether it is a phenomenon that 
occurs only in HIV-1C patients remain to be established. In both cases, fewer number of 
patients analysed at follow-up could be a possible limitation to draw conclusions. 
Published studies reporting impact of baseline tropism on standard first line ART outcome 
are scarce. While some studies showed patients harbouring X4 strains at baseline associated 
with poorer VL suppression or CD4+ T cell gain [76-79], few others reported similar rates 
[80, 81]. In our attempt to correlate the predicted tropism at baseline with outcome of 
standard ART at month six and 12, we did not find any significant association co-receptor for 
most comparisons. Thus, our study suggests that the clinical value for predicting outcome of 
ART by viral tropism as predicted by GTT is limited in an Ethiopian setting. We 
hypothesized that lack of a gold standard to compare with, which is usually a phenotypic test, 
could be a possible limitation of this study. We therefore decided to employ a phenotypic 
assay to compare with GTT predictions in Paper III. 
Results of our phenotypic assay showed that more than 90% of the tested isolates were R5 
tropic while no pure X4 tropic isolate was detected. When we compared the phenotypic 
results with GTT prediction by each of the five methods employed in previous paper, we 
found a varying degree of concordance. Moreover, early phenotypic studies reported that 
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HIV-1CEth strains are almost exclusively R5, even in patients with advanced 
immunodeficiency [65, 83], in contrast to our results in Paper I and II, which are based on 
prediction by GTT methods. Thus, results from Paper III suggest that these GTT tools have a 
suboptimal performance in describing the co-receptor usage of HIV-1CEth strains. Our result 
in Paper I might therefore have overestimated the increase in X4-tropic strains in the last two 
decades. Such overestimation is also supported by recent studies comparing GTT predictions 
with phenotypic results [152, 186]. Hence, available GTT algorithms need to be adapted 
further using larger phenotypic/genotypic data-set of HIV-1C to improve tropism prediction. 
It has been suggested that the CCR-co-receptor antagonist maraviroc could be a suitable 
alternative in HIV-1C dominating countries, but the above reported increase in proportion of 
X4 using HIV-1C strains argues against that. In order to elucidate this further, we attempted 
to analyse, whether there was a difference in sensitivity to maraviroc in vitro between pure 
R5 tropic and the dual tropic viruses. Our result demonstrated a dose response similar to the 
MJ4 isolate, a prototype for R5 using viruses, showing maraviroc’s in vitro effectiveness 
against R5 and dual-tropic HIV-1CEth isolates. Our finding is supported by a previous study 
which also demonstrated maraviroc’s effectiveness in vitro against viruses with dual-
characteristics, suggesting that the CCR5-antagonists may be a therapeutic-option in patients 
with dual/mixed-tropic viruses [49]. We acknowledge that small number of isolates included 
in our comparison could be a shortcoming to derive such conclusion. Yet, it should be noted 
that only six clones were found to be dual tropic and we compared maraviroc sensitivity of 
those samples with equal number of R5 tropic samples and tried to match source sample (the 
patient from which a given clone was derived) whenever possible. Thus, our limited data on 
the in vitro activity of maraviroc in dual tropic viruses could support the use of maraviroc as 
an alternative regimen, where available, as the vast majority of HIV-1CEth isolates are R5 
tropic and also dual tropic isolates showed sensitivity to this drug. 
Published studies showed TDR as a factor contributing to consequent virological failure 
[187-189], limiting first line treatment options. This is especially of concern after rapid 
rollout of ART in RLS. Although there are few published data from Ethiopia on the level of 
TDR, they are from small regional studies and countrywide data is lacking. We therefore 
attempted analysis of TDR, from patients enrolled to a first large nationwide ART cohort in 
Ethiopia [167, 168], employing both PBSS and NGS. Our results by PBSS using samples 
collected after six years of ART rollout (2005) showed a low TDR rate, with no difference 
between geographical regions. As the patients were recruited in 2009-2011, current situation 
of TDR may have been changed as prevalence of TDRMs has been shown to be directly 
correlated with length of ART availability in the area in question [190]. WHO’s recent report 
indicated that TDR in RLS is increasing over time [191] and TDRMs are of public health 
concern mainly in RLS as ART is initiated mostly at CD4 counts lower than 350 cells/μL in 
these settings. At such delayed initiation of ART, those mutations might already become 
minority variants, constituting less than 20% of virus population [190], which could be 
detected only by sensitive methods such AS-PCR or NGS. As most of the patients in our 
cohort (ACM study) had a low CD4 level at start of ART, the TDR rate might be 
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underestimated by PBSS. Earlier smaller studies from limited regions of Ethiopia using PBSS 
have reported low frequencies, 3.3% in 2003  and 0% in 2005 [192], which somewhat 
increased in later studies, 5.6% in 2008 [193], and 7.2% in 2010 [194]. However, our result 
from a larger nation-wide Ethiopian ACM cohort did not suggest an increasing trend of TDR. 
As mentioned above, most of our patients had a low CD4 during initiation of ART. Also, our 
earlier study based on sensitive allele-specific PCR detected NNRTI TDR at higher rate 
(6.5%) of in patients from one of the study sites for current study, Addis Ababa [195]. Hence, 
we decided to investigate for occurrence of minority variants by employing NGS in selected 
group of patients. As expected, higher number of sDRM was identified, where additional 
DRMs were detected in 17 patients. We acknowledge that selection of the patients included 
for NGS was biased. Yet, the observed discrepancy between PBSS and NGS indicates that 
NGS facilitates detection of sDRMs in RLS and reveals a higher prevalence of TDR to the 
same or lower cost [196]. 
Since integrase strand transfer inhibitors (INSTIs) are planned to be used in some African 
countries recently, we analysed our NGS data and major INSTI mutations (T66I, E138K, 
Q148R, and Q148H) were found in five patients. During the period when samples were 
collected (2009-2011), and until now, INSTIs are not an integrated part of the ART regimens 
in Ethiopia. Furthermore, no clustering of those strains with INSTIs DRM could be revealed 
by the phylogenetic analysis (figure 2, paper IV). Rather, the patients were from five different 
ACM study sites, rendering possible transmission of these strains from INSTI treated subjects 
unlikely. One explanation for this occurrence could be that wild-type HIV-1C strains might 
harbour low abundance of INSTI DRMs. Hence, this phenomenon needs further investigation 
of minor quasispecies with regard to INSTI DRMs in RLS.  
Studies attempted to elucidate the impact of pre-existing INSTI DRMs on treatment outcome, 
where low abundance INSTI DRMs had no impact in earlier studies [197, 198], while the 
E157Q mutation has been reported in 1.7%- 5.6% of ART-naïve patients in recent studies, 
depending on subtype[199] and been implied to affect treatment response [200]. However, 
those earlier studies used AS-PCR with the sensitivity to detect a significantly lower 
proportion of mutants than our NGS method with 1% cut-off. Therefore, a potential clinical 
impact of our findings still remains to be evaluated. 
In summary, this thesis provides key information about  HIV epidemic in Ethiopia, where the 
most prevalent and successful HIV-1 subtype in terms of global spread, HIV-1 C, was 
described for the first time three decades back.  Moreover, it correlates molecular 
characteristics of the virus, mainly co-receptor tropism and drug resistance mutations, at 
baseline with treatment outcome of standard ART. Although the thesis is based on analysis of 
samples and patient data from HIV-1C infected Ethiopians, the findings are of global 
importance as HIV-1C is rapidly spreading throughout the globe and changing the 
epidemiology in many countries, especially western countries previously dominated by HIV-
1B as a result of recent migrant influx.  
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6 CONCLUSIONS AND FUTURE PERSPECTIVES 
Main conclusions of the thesis are: 
I. After its estimated introduction to Ethiopia in 1970’s, the HIV-1 epidemic is still 
monophylogenetic in all geographical regions of Ethiopia, almost exclusively 
comprised of HIV-1C, and dominated by R5-tropic virus, even in patients with 
advanced immunodeficiency.  
 
II. Each of the commonly used GTT tools predicted co-receptor usage with 
comparable frequency nonetheless with large discordance between the methods 
underestimating the presence of R5 and overestimating X4 strains compared to a 
phenotypic assay. Available GTT algorithms need to be thus adapted further using 
HIV-1C phenotypic/genotypic data set to improve prediction. 
 
III. Baseline tropism predicted by C-PSSM method showed an impact on outcome of 
standard first line ART at month 12 and hence could be possibly used for 
prediction of ART outcome in HIV-1C infected Ethiopians.  
 
IV. Maraviroc has an in vitro activity against most HIV-1C viruses and could be 
considered as an alternative regimen in HIV-1C infected individuals if afforded.    
 
V. NGS detected sDRM more often than PBSS and major INSTI DRMs were 
identified in minor viral variants.  
 
VI. Pre-treatment DRMs were associated with a poorer treatment outcome. The high 
rate of TDR and the identification of pre-existing INSTI DRMs at baseline by 
NGS highlights the importance of TDR surveillance in RLS and shows added 
value of high-throughput NGS.  
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